Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Radiopharmaceuticals Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The radiopharmaceuticals market size has experienced rapid expansion in recent years. This market is projected to expand from $7.3 billion in 2025 to reach $8.25 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 13.0%. Historically, this growth has been driven by factors such as the increasing adoption of nuclear imaging technologies, a rise in cancer diagnosis rates, the ready availability of radioisotopes, the expansion of hospital-based nuclear medicine facilities, and successful regulatory approvals for diagnostic agents.
The radiopharmaceuticals market is anticipated to observe considerable expansion over the next few years. It is forecast to grow to $13.68 billion in 2030, achieving a compound annual growth rate (CAGR) of 13.5%. This growth during the projected period stems from developments in precision oncology, a rising demand for targeted radiotherapies, the increase in diagnostic imaging centers, investments in cyclotron infrastructure, and technological improvements in isotope production. Key trends for the forecast period encompass an increasing utilization of radiopharmaceuticals in oncology, the growth of theranostics applications, the broadening of PET and SPECT imaging, enhanced development of targeted radiotherapies, and improvements in nuclear medicine infrastructure.
Get A Free Sample Report With In-Depth Market Insights:
Radiopharmaceuticals Market Growth Momentum: What Factors Are Shaping Demand?
The rising incidence of cancer and cardiovascular diseases is anticipated to fuel the demand for the radiopharmaceuticals market. Radiopharmaceuticals are becoming recognized as a secure and potent therapeutic choice, surpassing traditional medicines. They offer radiologists an advantage in managing cancer and cardiovascular diseases, thanks to benefits like targeted therapy. Globally, cancer ranks as the second leading cause of fatality, accounting for approximately 1 in 6 deaths. For example, in April 2024, data from the International Agency for Research on Cancer (IARC), a specialized agency based in France, revealed that in 2022, almost 20 million new cancer cases and 9.7 million deaths linked to cancer were recorded worldwide. These figures are forecast to escalate by 2040, reaching an annual total of 29.9 million new cases and 15.3 million deaths. Consequently, the growing number of cancer and cardiovascular disease cases is poised to significantly boost the demand for radiopharmaceuticals in their treatment.
Radiopharmaceuticals Market Segments: Where Is Growth Concentrated?
The radiopharmaceuticals market covered in this report is segmented –
1) By Type: Diagnostic, Therapeutic
2) By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Musculoskeletal, Respiratory, Nephrology, Other Applications
3) By End User: Hospitals And Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes
Subsegments:
1) By Diagnostic: Positron Emission Tomography (PET) Radiopharmaceuticals, Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals
2) By Therapeutic: Alpha Emitters, Beta Emitters, Brachytherapy
Radiopharmaceuticals Market Trends Redefining Industry Growth
Major companies operating in the radiopharmaceuticals market are increasingly forming strategic partnerships to accelerate innovation and expand access to advanced diagnostic and therapeutic solutions. These collaborations focus on enhancing radiopharmaceutical development, strengthening regional production capabilities, and supporting the growing demand for precision imaging and targeted therapies. For instance, in June 2023, the University of Pittsburgh Medical Center (UPMC), a US-based hospital system, partnered with PharmaLogic Holdings Corporation to co-develop and manufacture new radiopharmaceuticals at a Pittsburgh facility. The partnership aims to expand patient and clinician access to cutting-edge diagnostic and therapeutic agents that are not currently available in nearby regions. Under the non-exclusive agreement, UPMC and PharmaLogic will translate experimental radiopharmaceuticals into clinically useful medications, supporting broader commercialization and accelerating the adoption of novel nuclear medicine treatments.
Radiopharmaceuticals Market Key Participants And Competitive Landscape
Major companies operating in the radiopharmaceuticals market are Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, ÚJV Rež, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacýbaþý-Monrol Nuclear Products, NTP Radioisotopes.
View The Full Radiopharmaceuticals Market Report:
Radiopharmaceuticals Market Top Region By Revenue And Market Share
North America was the largest region in the global radiopharmaceuticals market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the radiopharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
